Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Russian
  • Portuguese
  • Polish

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Aspirin: antibiotic effect in colorectal cancer?
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
General Medicine

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Aspirin: antibiotic effect in colorectal cancer?
Gastroenterology

Aspirin: antibiotic effect in colorectal cancer?

Cancer
Gastroenterology Oncology

Known for its anti-inflammatory effects, aspirin also acts as an antibiotic on certain bacteria involved in colorectal cancer. It may even prevent tumorigenesis, both in vitro and in vivo.

Gastroenterology
Gynecology
Pediatrics
General Medicine
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail

About this article

Created 16 November 2021
Updated 17 July 2024

There is increasing understanding of the clinical correlations and potential mechanistic roles of specific members of the gut and tumoral microbiota in colorectal cancer (CRC) initiation, progression, and survival. Despite this, we are still a long way from defining microbially-informed diagnostic, preventive, or therapeutic approaches. However, a step forward has just been made, with a team recently showing that aspirin, a chemopreventive agent recommended by the (sidenote: United States Preventive Services Task Force An independent, volunteer panel of US experts in disease prevention and evidence-based medicine. 
 
)
 for the prevention of CRC, has specific effects on (sidenote: Fusobacterium nucleatum Increased presence in human colonic adenomas and CRCs, responsible for tissue proliferation in vitro and in animal models. ) , a bacterium associated with this disease.

In vitro and in vivo effect

US researchers have recently shown that aspirin disrupts the growth of the Fn7-1 strain of F. nucleatum, and even kills it, in vitro, in human colonic adenoma tissue cultures. At levels that do not inhibit bacterial growth, aspirin influenced the gene expression of Fn7-1: 55 genes were upregulated and 155 genes downregulated.

To assess aspirin’s role as a modulator of F. nucleatum growth, the researchers also conducted in vivo experiments. In a murine model, Fn7-1 was orally inoculated daily to induce an intestinal tumor, but mice receiving an aspirin-enriched diet saw inhibited tumorigenesis when compared to those on a normal diet. The protective effect of aspirin was also found with other strains of F. nucleatum, including some isolates from human CRC tissues, the latter proving more sensitive than the Fn7-1 strain. Conversely, this protective effect was much milder with other CRC-associated microbes, such as enterotoxigenic Bacteroides fragilis and colibactin-producing Escherichia coli.

Lastly, a (sidenote: Quantitative PCR  Specific PCR (polymerase chain reaction) method used to measure the initial quantity of DNA. 
 
)
 performed on adenoma DNA samples of patients taking aspirin daily showed a 2 to 3-fold lower fusobacterial abundance than in samples taken from control patients. This result suggests that the modulatory effect observed in vitro also occurs in humans.

Antibiotic effect in addition to anti-inflammatory effect

These data confirm the direct antibiotic effect of aspirin on strains of F. nucleatum. Its protective effect against colorectal cancer and adenomas thus exceeds its anti-inflammatory role. Consideration of the potential effects of aspirin on the microbiome holds promise in optimizing risk-benefit assessments for the drug’s use in CRC prevention and management. However, it is unlikely that the anti-inflammatory effects of aspirin alone are enough to stop tumorigenesis in its entirety. Further research is required before its use to improve the prognosis of CRC – the second leading cause of cancer death worldwide – can be considered.

Sources

Brennan CA, Nakatsu G, Gallini Comeau CA, et al. Aspirin Modulation of the Colorectal Cancer-Associated Microbe Fusobacterium nucleatum. mBio. 2021 Apr 6;12(2):e00547-21. 

Tags
Colorectal cancer CRC Microbiome Flora

    See also

    Newsletter 4 - article 1 The role of Fusobacterium in colorectal cancer
    Actu PRO : E. coli signe son rôle dans le cancer colorectal Mutational signature of E. coli in colorectal cancer
    Created 16 November 2021
    Updated 17 July 2024

    About this article

    To know more about this topic.

    Main topic

    Cancer

    Medical practice

    Gastroenterology Oncology

    Content type

    News
    Gastroenterology

    Association between fungal dysbiosis and environment

    The fungal portion of the gut microbiota (or mycobiota) has been much less studied than the bacterial...

    Find out more

    Your IBS Diagnosis Check List

    How many patients suffering from gut disorder do you see per week? How many are diagnosed with Irrita...

    Find out more

    Probiotics: what exactly are we talking about?

    From the Latin pro and Greek bios meaning “for life”, the term “probiotic” was suggested over 60 year...

    Find out more

    How do you choose a probiotic for your patient?

    Faced with a plethora of products on the market, it's not always easy for health professionals to sug...

    Find out more

    The Janus face of Antibiotics: Life Savers and Microbiota Disruptors

    A page turns: with the advent of antibiotics in the...

    Find out more

    Fecal transplantation - ready for prime time?

    Congress review By Pr. Danny De Looze Department of Gastroenterology University Hospital Gent, Belgi...

    Find out more

    Focus on antibiotic associated diarrhea (AAD)

    Find out more

    Dampening gastrointestinal inflammation through nutrition

    by Dr Genelle Healey

    Find out more

    Continue reading

    News
    07.02.2025

    Your functional dyspepsia diagnosis check list

    Read the article
    17.04.2025

    Sensitivity to the additive E466: the role of the microbiota

    Read the article
    Photo HCPs: Clinical context over quick fix: the fresh consensus on microbiome testing
    11.04.2025

    Clinical context over quick fix: the fresh consensus on microbiome testing

    Read the article
    22.11.2023

    Is vaginal microbiota transfer the new miracle for C-section babies?

    Read the article
    Actu PRO : Alcoolisme : expliquer les troubles sociaux grâce au microbiote
    27.01.2021

    Alcoholism: explaining social disorders thanks to the microbiota

    Read the article
    20.03.2025

    Entacapone and the gut: a hidden impact on parkinson’s care

    Read the article
    07.03.2025

    When diet and microbiota influence endometriosis

    Read the article
    28.02.2025

    The gut microbiota and sleep disorder: a therapeutic approach based on modulation of the microbiota?

    Read the article
    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine
    • English
    • Français
    • Español
    • Russian
    • Portuguese
    • Polish

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    02.05.2025

    A new lens on chlamydia: beyond behavior, into the microbiome

    Read the article
    17.04.2025

    Sensitivity to the additive E466: the role of the microbiota

    Read the article
    Photo HCPs: Clinical context over quick fix: the fresh consensus on microbiome testing
    11.04.2025

    Clinical context over quick fix: the fresh consensus on microbiome testing

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    © 2025 Biocodex. All rights reserved.

    • Legal notice
    • GTU
    • Data protection policy
    • Sitemap
    • Cookies settings
    • Digital accessibility : partially compliant
    Biocodex logo